TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from Hua Medicine ( (HK:2552) ) is now available.
Hua Medicine announced a significant turnaround in its financial performance for the first half of 2025, reporting an expected profit of RMB1,184.1 million compared to a loss in the same period in 2024. This improvement is attributed to the termination of an agreement with Bayer, leading to a release of contract liabilities, and successful commercialization efforts for HuaTangNing, resulting in a 111.8% increase in sales and improved gross profit margins.
More about Hua Medicine
Hua Medicine is a pharmaceutical company focused on the development and commercialization of innovative therapies for diabetes. The company has assumed full responsibility for the commercialization of HuaTangNing in mainland China, enhancing its market presence in the diabetes treatment sector.
YTD Price Performance: 162.33%
Average Trading Volume: 8,192,394
Technical Sentiment Signal: Buy
Current Market Cap: HK$3.72B
Learn more about 2552 stock on TipRanks’ Stock Analysis page.